Pancreatic ductal adenocarcinoma (PDAC) · line 1 · FOLFIRINOX

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-FOLFIRINOX`

ID	`IND-PDAC-METASTATIC-1L-FOLFIRINOX`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-PDAC`
Sources	`SRC-ESMO-PANCREATIC-2024` `SRC-NCCN-PANCREATIC-2025`

Notes

Scaffold — gem-nab-pac alternative + olaparib BRCA-maintenance + adjuvant mFOLFIRINOX await full authoring.

Used By

Algorithms

ALGO-PDAC-METASTATIC-1L - ALGO-PDAC-METASTATIC-1L

Indication

IND-PDAC-ADJUVANT-MFOLFIRINOX - IND-PDAC-ADJUVANT-MFOLFIRINOX
IND-PDAC-LAPC-CHEMORADIATION - IND-PDAC-LAPC-CHEMORADIATION
IND-PDAC-METASTATIC-1L-NALIRIFOX - IND-PDAC-METASTATIC-1L-NALIRIFOX

Red flag

RF-PDAC-FIT-FOR-FOLFIRINOX - Fitness for FOLFIRINOX in metastatic PDAC per PRODIGE-4 / ACCORD-11 inclusion criteria (C...